Ralliant (NYSE:RAL) Sets New 52-Week High Following Strong Earnings

Shares of Ralliant Corporation (NYSE:RAL) reached a new 52-week high on Tuesday after the company announced better than expected quarterly earnings. The stock traded as high as $60.14 and last traded at $56.7890, with a volume of 1357745 shares changing hands. The stock had previously closed at $49.56.

The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million for the quarter. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, June 8th. Ralliant’s payout ratio is 10.20%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Royal Bank Of Canada decreased their price target on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 6th. Barclays lowered their price objective on shares of Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Oppenheimer dropped their target price on Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, February 6th. Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a research report on Friday, February 6th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Ralliant in a research report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.50.

Insider Buying and Selling

In related news, SVP Karen M. Bick sold 2,530 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $46.50, for a total value of $117,645.00. Following the transaction, the senior vice president owned 42,652 shares in the company, valued at $1,983,318. The trade was a 5.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Institutional Investors Weigh In On Ralliant

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Phocas Financial Corp. grew its holdings in shares of Ralliant by 81.2% in the fourth quarter. Phocas Financial Corp. now owns 157,116 shares of the company’s stock valued at $7,999,000 after acquiring an additional 70,403 shares in the last quarter. Vanguard Group Inc. boosted its position in Ralliant by 10.7% during the third quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock worth $637,995,000 after purchasing an additional 1,415,327 shares during the period. Welch & Forbes LLC bought a new stake in Ralliant during the 3rd quarter valued at $854,000. SG Capital Management LLC purchased a new stake in Ralliant during the 3rd quarter worth about $8,139,000. Finally, Thrivent Financial for Lutherans boosted its position in shares of Ralliant by 60.5% in the third quarter. Thrivent Financial for Lutherans now owns 210,045 shares of the company’s stock valued at $9,185,000 after acquiring an additional 79,173 shares during the period.

Ralliant Price Performance

The business’s 50-day moving average price is $44.32 and its 200 day moving average price is $47.07. The stock has a market capitalization of $6.39 billion and a PE ratio of 29.08. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.